Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).

2014-07-23 16:20:31 | BioPortfolio

Summary

Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the treatment of trauma nightmares and sleep disturbance in combat veterans with PTSD, and alcohol dependence.

The objective of this study is to evaluate the efficacy of prazosin (16mg) versus placebo in reducing alcohol consumption and decreasing symptoms of PTSD in patients with comorbid AD and PTSD.

Description

Background:

There is a high rate of comorbidity with alcohol dependence (AD) and post traumatic stress disorder (PTSD). The rates of PTSD among individuals with AD are at least twice as high as those in the general population. In addition, alcohol dependence is the most common comorbid condition in men with PTSD. Despite this, little is known about how to best treat individuals with comorbid AD and PTSD. The use of an alpha-1 adrenergic receptor antagonist represents a novel approach to treatment that may target symptoms of both AD and PTSD. There is evidence of common neurobiological mechanisms that underlie both AD and PTSD. Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the treatment of trauma nightmares and sleep disturbance in combat veterans with PTSD, and alcohol dependence.

Objective:

The objective of this study is to evaluate the efficacy of prazosin (16mg) versus placebo in reducing alcohol consumption and decreasing symptoms of PTSD in patients with comorbid AD and PTSD. Methods: Thirty participants with a current diagnosis of AD and PTSD will be enrolled in a 13-week trial. They will be assigned, in a double-blind fashion, to either prazosin or placebo. Significance: This project will be the first to compare prazosin to placebo as effective treatments for reducing alcohol consumption and PTSD symptoms in patients with both AD and PTSD.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Conditions

Alcohol Dependence

Intervention

Prazosin

Location

VA Connecticut Healthcare System
West Haven
Connecticut
United States
06516

Status

Recruiting

Source

Yale University

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T16:20:31-0400

Clinical Trials [592 Associated Clinical Trials listed on BioPortfolio]

Study of the Medication Prazosin for Alcohol Dependence

The purpose of this study is to determine whether the drug prazosin is effective for the treatment of alcohol dependency.

Stress Reactivity in Veterans Receiving Pharmacological Treatment for Post-Traumatic Stress Disorder (PTSD) and Alcohol Dependence

Method: This study is designed as an accompaniment to an already funded study - a 12-week treatment trial with prazosin for patients with PTSD and AD. The study design will consist of III...

Prazosin for ETOH or Cocaine Craving

This double-blind placebo controlled crossover pilot trial will test the hypothesis that prazosin, an alpha-1 adrenergic receptor antagonist, reduces craving for their drug of choice in co...

A Placebo-Controlled Trial of Memantine for Alcohol Dependence

The purpose of this study is to obtain a preliminary indication of the safety and effectiveness of oral memantine (40 mg/day) in alcohol dependent patients. This study is a 16-week study ...

Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence

The purpose of this study is to see whether naltrexone is safe and useful in preventing alcohol relapse, as well as in decreasing craving for alcohol in people with a diagnosis of alcohol ...

PubMed Articles [3230 Associated PubMed Articles listed on BioPortfolio]

Prazosin Reduces Alcohol Intake in an Animal Model of Alcohol Relapse.

Many alcoholics and heavy drinkers undergo repeated cycles of alcohol abstinence followed by relapse to alcohol drinking; a pattern that contributes to escalated alcohol intake over time. In rodents, ...

Further Analyses of Genetic Association Between GRM8 and Alcohol Dependence Symptoms Among Young Adults.

The gene GRM8, a metabotropic glutamate receptor, has emerged as a gene of interest for its possible role in the development of alcohol dependence, with evidence of association with an electrophysiolo...

Patterns of use of other drugs among those with alcohol dependence: Associations with drinking behavior and psychopathology.

Alcohol dependence (AD) presents with substantial clinical heterogeneity, including concurrent use of non-alcohol drugs. Here, we examine specific patterns of concurrent non-alcohol substance use duri...

Quantitative electroencephalography analysis in university students with hazardous alcohol consumption, but not alcohol dependence.

Hazardous alcohol consumption is a pattern of consumption that leads to a higher risk of harmful consequences either for the user or for others. This pattern of alcohol consumption has been linked to ...

Duration of therapeutic remission alcohol dependence: a role of dopamine system genes polymorphism and family history density.

A quantitative assessment of the impact of genetic factors (density of family history of alcohol dependence and dopamine system genes polymorphisms) on the average time to relapse (ATR) after alcohol ...

Medical and Biotech [MESH] Definitions

A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)

Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

Strong dependence, both physiological and emotional, upon morphine.

Strong dependence, both physiological and emotional, upon heroin.

Substances interfering with the metabolism of ethyl alcohol, causing unpleasant side effects thought to discourage the drinking of alcoholic beverages. Alcohol deterrents are used in the treatment of alcoholism.

More From BioPortfolio on "Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD)."


Advertisement
 

Relevant Topics

Sleep Disorders
Latest News Clinical Trials Research Drugs Reports Corporate
Sleep disorders disrupt sleep during the night, or cause sleepiness during the day, caused by physiological or psychological factors. The common ones include snoring and sleep apnea, insomnia, parasomnias, sleep paralysis, restless legs syndrome, circa...

Stress
Latest News Clinical Trials Research Drugs Reports Corporate
Stress is caused by your perception of situations around you and then the reaction of your body to them. The automatic stress response to unexpected events is known as 'fight or flight'. Discovered by Walter Cannon in 1932, it is the release of h...

Anxiety Disorders
Latest News Clinical Trials Research Drugs Reports Corporate
Anxiety is caused by stress. It is a natural reaction, and is beneficial in helping us deal with tense situations and pressure. It is deterimental when is becomes an excessive, irrational dread of everyday situations. The most common types of anxiety di...

Advertisement